FDA recalls GONAK ophthalmic drug solution for manufacturing deviations
Akorn voluntarily recalled 196,254 bottles of GONAK ophthalmic solution nationwide due to CGMP manufacturing practice deviations. This professional-use eye solution is employed in gonioscopic examinations.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is a Class II voluntary recall initiated by the manufacturer due to CGMP deviations. No illnesses or injuries are reported in the source. The rubric specifies that voluntary precautionary recalls are classified as Moderate.
Plain-English summary
Akorn, Inc. initiated a voluntary recall of GONAK Hypromellose Ophthalmic Demulcent Solution, a professional-use eye drop solution for gonioscopic examinations. The product is supplied in 15 mL dropper bottles containing 2.5% hypromellose (25 mg formulation), with NDC 17478-064-12.
The recall was issued due to Current Good Manufacturing Practice (CGMP) deviations. Akorn initiated the recall on October 13, 2022, and the FDA classified it as a Class II recall on January 13, 2023.
Approximately 196,254 bottles were distributed nationwide in the United States. Multiple lot numbers are affected with expiration dates ranging from January 2023 through November 2023.
This recall remains ongoing. Healthcare professionals and facilities should verify inventory against the provided lot numbers and expiration dates to identify affected products.
The recalled product
- Product
- GONAK Hypromellose Ophthalmic Demulcent Solution, (25 mg) 2.5%, 15 mL per dropper bottle, For Professional Use in Goinoscopic Examinations, Mfd. by: Akorn, INc., Lake Forest, IL 60045. NDC: 17478-064-12
- Manufacturer
- Akorn, Inc.
- Category
- Drug — Ophthalmic Solution
- Hazard
- cgmp-deviation
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- Lot: 0C80A
- EXP 2/28/2023
- 0B71A
- 1B32A
- EXP 1/31/2023
- 0C80B
- 0F68A
- EXP 5/31/2023
- 0G85A
- 0G01A
- 1G54A
- 1G71A
- EXP 6/30/2023
- 0H32A
- 0H47A
- 1H75A
- EXP 7/31/2023
- 0K22A
- EXP 9/30/2023
- 0M90A
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27